time. This protocol, merging visiblelight photoredox and palladium catalysis, provides a direct approach to conjugated tertiary allylic alcohol derivatives with broad functional group tolerance in moderate to excellent yields. Mechanistic studies suggest that, although two possible pathways exist in the transformation, radical oxyalkenylation promoted by visiblelight photoredox takes over the major
Regioselective Vinylation of Remote Unactivated C(sp<sup>3</sup>)−H Bonds: Access to Complex Fluoroalkylated Alkenes
作者:Shuo Wu、Xinxin Wu、Dongping Wang、Chen Zhu
DOI:10.1002/anie.201812927
日期:2019.1.28
particular functional group into aliphatic sites by direct activation of unreactive C−H bonds is of great synthetic value. Despite advances in radical‐mediated functionalization of C(sp3)−H bonds by a hydrogen‐atom transfer process, the site‐selective vinylation of remote C(sp3)−H bonds still remains underexplored. Reported herein is a new protocol for the regioselective vinylation of unactivatedC(sp3)−H
[EN] PYRAZOLIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS<br/>[FR] COMPOSES DE PYRAZOLIDINONE UTILISES COMME LIGANDS DES RECEPTEURS EP2 ET/OU EP4 AUX PROSTAGLANDINES
申请人:APPLIED RESEARCH SYSTEMS
公开号:WO2003035064A1
公开(公告)日:2003-05-01
The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.
Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
申请人:——
公开号:US20040254233A1
公开(公告)日:2004-12-16
The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.
PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS
申请人:ARALDI Gian Luca
公开号:US20080234346A1
公开(公告)日:2008-09-25
The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors.